Last reviewed · How we verify
Amiodarone Pill
Amiodarone blocks multiple cardiac ion channels (sodium, potassium, calcium, and beta-adrenergic) to slow electrical conduction and suppress abnormal heart rhythms.
Amiodarone blocks multiple cardiac ion channels (sodium, potassium, calcium, and beta-adrenergic) to slow electrical conduction and suppress abnormal heart rhythms. Used for Atrial fibrillation (maintenance of sinus rhythm and rate control), Ventricular tachycardia and ventricular fibrillation, Supraventricular tachycardia refractory to other agents.
At a glance
| Generic name | Amiodarone Pill |
|---|---|
| Also known as | Cordarone |
| Sponsor | Our Lady of the Lake Hospital |
| Drug class | Class III antiarrhythmic agent |
| Target | Potassium channels (hERG), sodium channels, L-type calcium channels, beta-adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Amiodarone is a Class III antiarrhythmic agent that primarily prolongs the action potential duration and refractory period by blocking potassium channels. It also has Class I, II, and IV properties, blocking sodium, beta-adrenergic, and calcium channels respectively. This multi-channel blockade makes it effective for suppressing both atrial and ventricular arrhythmias.
Approved indications
- Atrial fibrillation (maintenance of sinus rhythm and rate control)
- Ventricular tachycardia and ventricular fibrillation
- Supraventricular tachycardia refractory to other agents
Common side effects
- Pulmonary toxicity (pneumonitis, fibrosis)
- Thyroid dysfunction (hypo- or hyperthyroidism)
- Hepatotoxicity
- Corneal microdeposits
- Photosensitivity
- Bradycardia
- QT prolongation
- Torsades de pointes
Key clinical trials
- Oral Amiodarone for Acute Cardioversion of Atrial Fibrillation Study (PHASE4)
- The Modified "Pills-in-the-Pocket" Strategy (NA)
- Rapid Atrial Fibrillation Treatment Strategy (PHASE4)
- Safety of Amiodarone and Ranolazine Together in Patients With Angina (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amiodarone Pill CI brief — competitive landscape report
- Amiodarone Pill updates RSS · CI watch RSS
- Our Lady of the Lake Hospital portfolio CI